Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
118 results
- FREEDOM-EVIndependent statistical analysis of FREEDOM-EV, a randomized phase 3 trial of treprostinil diolamine versus placebo in pulmonary arterial hypertension, covering clinical worsening, 6-minute walk distance, NT-proBNP, functional class, statistical methods, and safety.
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GOG-0218Independent statistical analysis of GOG-0218, a randomized phase 3 trial of carboplatin and paclitaxel with or without bevacizumab in patients with stage III or stage IV ovarian, primary peritoneal, or fallopian tube…
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- Hokusai-VTEA complete statistical analysis of Hokusai-VTE, the randomized phase 3 trial comparing heparin/edoxaban with heparin/warfarin for symptomatic venous thromboembolism, including non-inferiority analysis, Cox modeling, bleeding outcomes, and statistical interpretation.
- HPTN 052Independent statistical analysis of HPTN 052, a randomized phase 3 trial evaluating early versus delayed antiretroviral therapy and linked and all partner HIV infection rates.
- HPTN 083Independent statistical analysis of HPTN 083, a randomized phase 2/3 trial comparing injectable cabotegravir with TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex with men.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- KEYNOTE-006Independent statistical analysis of KEYNOTE-006, a randomized phase 3 trial comparing two pembrolizumab dosing schedules with ipilimumab in participants with advanced melanoma.
- KEYNOTE-024Independent statistical analysis of KEYNOTE-024 (NCT02142738), including randomized trial design, progression-free survival, overall survival, objective response rate, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-045Independent statistical analysis of KEYNOTE-045, a randomized phase 3 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in advanced urothelial cancer, including primary and secondary endpoint results and statistical interpretation.
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-062Independent statistical analysis of KEYNOTE-062, a randomized phase 3 trial of pembrolizumab monotherapy and pembrolizumab plus standard chemotherapy in advanced gastric adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- KEYNOTE-119Independent statistical analysis of KEYNOTE-119, a randomized phase 3 trial comparing single-agent pembrolizumab with single-agent chemotherapy in metastatic triple negative breast cancer, including overall survival, response, progression-free survival, statistical methodology, and interpretation.
- KEYNOTE-361Independent statistical analysis of KEYNOTE-361, the randomized phase 3 trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma, including primary and secondary endpoint analyses, statistical methods,…
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- LEADERComplete statistical analysis of the LEADER phase 3 trial of liraglutide versus placebo in type 2 diabetes, including trial design, cardiovascular time-to-event endpoints, Cox regression, non-inferiority and superiority testing, secondary outcomes, safety,…
- LEAP-002Independent statistical analysis of LEAP-002, the randomized phase 3 trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line therapy in advanced hepatocellular carcinoma.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 8Independent statistical analysis of LUX-Lung 8, the phase 3 randomized trial of afatinib versus erlotinib in squamous cell lung cancer after at least one prior platinum-based chemotherapy. Includes progression-free survival, overall survival,…
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- ODINIndependent statistical analysis of the ODIN phase 3 trial comparing once-daily versus twice-daily darunavir/ritonavir in early treatment-experienced HIV-1 infected patients, including non-inferiority methodology, logistic regression, ANCOVA, Cox models, confidence intervals, and reported…
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- PARAGON-HFIndependent statistical analysis of PARAGON-HF, evaluating LCZ696 versus valsartan in heart failure with preserved ejection fraction, including primary and secondary endpoint analyses, statistical methods, interpretation, and limitations.
- Partners PrEPAn independent statistical analysis of the Partners PrEP phase 3 trial, examining TDF and FTC/TDF for prevention of HIV-1 acquisition in HIV-1 discordant couples, including Cox regression, hazard ratios, safety, longitudinal analyses,…
- PEARLSIndependent statistical analysis of the PEARLS phase 3 trial of pembrolizumab versus placebo after resection in non-small cell lung cancer, including disease-free survival, Cox regression, hazard ratios, confidence intervals, one-sided testing, and…
- PIONEER 6Independent statistical analysis of PIONEER 6, the randomized phase 3 trial of oral semaglutide versus placebo in subjects with type 2 diabetes, including its MACE endpoint, non-inferiority analysis, Cox model, hazard ratio,…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PRoFESSAn independent statistical analysis of PRoFESS (NCT00153062), including its randomized double-blind design, recurrent-stroke endpoints, Cox proportional-hazards analyses, non-inferiority framework, hazard ratios, confidence intervals, and secondary outcomes.
- PROfoundIndependent statistical analysis of the PROfound phase 3 trial of olaparib versus investigators' choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer, including trial design, time-to-event and response…
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RE-COVER IIIndependent statistical analysis of RE-COVER II, a randomized phase 3 trial comparing dabigatran etexilate with warfarin for treatment of acute symptomatic venous thromboembolism, including non-inferiority and time-to-event analyses.
- RE-LYComplete statistical analysis of the RE-LY phase 3 trial of dabigatran versus warfarin, including randomized trial design, time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority and superiority comparisons, safety, and statistical interpretation.
- RE-SPECT ESUSIndependent statistical analysis of RE-SPECT ESUS, the randomized phase 3 trial of dabigatran etexilate versus aspirin for secondary stroke prevention after embolic stroke of undetermined source. Includes trial design, time-to-event endpoints, Cox…
- REACTComplete statistical analysis of the REACT trial (NCT01329029), evaluating roflumilast versus placebo in patients with chronic obstructive pulmonary disease treated with fixed LABA and inhaled glucocorticosteroid combinations.
- REWINDComplete statistical analysis of the REWIND phase 3 trial of dulaglutide versus placebo in type 2 diabetes and cardiovascular disease, including its randomized design, time-to-event endpoints, Cox proportional-hazards analysis, cardiovascular outcomes, and…
- ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RUXCOVIDIndependent statistical analysis of the phase 3 RUXCOVID trial of ruxolitinib versus placebo in patients with COVID-19 associated cytokine storm, including the primary composite endpoint, secondary outcomes, statistical methods, safety, and interpretation.
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- S-TRACIndependent statistical analysis of the S-TRAC phase 3 trial of sunitinib versus placebo in patients at high risk of recurrent renal cell cancer, including disease-free survival, overall survival, trial design, Cox modeling,…
- SCOREDIndependent statistical analysis of SCORED (NCT03315143), a randomized phase 3 trial of sotagliflozin versus placebo in participants with type 2 diabetes and moderate renal impairment at cardiovascular risk. Includes the primary cardiovascular…
- SELECTAn independent statistical analysis of the SELECT phase 3 trial of semaglutide versus placebo in patients with overweight or obesity, including trial design, the primary time-to-event endpoint, Cox proportional-hazards analysis, and interpretation.
- SHIFTComplete statistical analysis of SHIFT, a randomized phase 3 trial evaluating ivabradine versus placebo in patients with chronic heart failure, including Cox proportional-hazards methods, hazard ratios, confidence intervals, p-values, safety, and statistical…